Who is sponsoring NCT02289950?

NCT02289950 is sponsored by Eisai Inc..

What condition does NCT02289950 study?

NCT02289950 studies Platinum-Sensitive Ovarian Cancer in First Relapse.

What drugs are being tested in NCT02289950?

Interventions: Farletuzumab, Placebo.

What is the status of NCT02289950?

NCT02289950 is currently COMPLETED.

Last reviewed 2021-09-02 · How we verify

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

NCT02289950 PHASE2 COMPLETED Results posted

MORAb-003-011 is a global, multicenter, double-blind, randomized placebo-controlled study to assess the safety and efficacy of farletuzumab in combination with standard chemotherapy in subjects with low cancer antigen 125 (CA125) platinum-sensitive ovarian cancer in first relapse.

Details

Lead sponsor	Eisai Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	332
Start date	Thu Mar 19 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Platinum-Sensitive Ovarian Cancer in First Relapse

Interventions

Farletuzumab
Placebo

Countries

Italy, Japan, Belgium, United Kingdom, Germany, United States, Spain